摘要
目的探讨重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白依那西普对中重度寻常性银屑病的疗效。方法2008年2月至2011年12月，诊断为中重度寻常性银屑病且经治疗疗效差的患者24例，给予抗肿瘤坏死因子靶向治疗（依那西普25mg皮下注射，每周2次，疗程3个月），随访6个月，按银屑病面积和严重程度指数（PAsI）和医师整体评估标准（PGA）对疗效进行评分。结果经依那西普治疗24周后，24例寻常性银屑病PASI减少75％的有12例（50％），1例无效，4例注射部位有红肿等不良反应。结论对于其他治疗疗效不佳的中重度寻常性银屑病患者，用抗肿瘤坏死因子治疗有效。
Objective To evaluate the efficacy profile of etanercept,a recombinant human type II tumor necrosis factor receptor-Fc fusion protein, in patients with moderate to severe psoriasis. Methods A retrospective study was performed. This study included 24 patients with moderate to severe psoriasis vulgaris resistant to conventional therapy. They were treated with subcutaneous injection of etanercept 25 mg twice weekly for three months during February 2008 and August 2011. Six months of follow up was carried out. Clinical efficacy was evaluated by psoriasis area and severity index （PASI） and physician global assessment （PGA）. Results After 24- week treatment, 12 （50%） patients achieved a 75% reduction in PASI score, 1 （4.2%） patient failed to respond. Adverse reaction, such as erythematous swelling at the injection site, was observed in 4 patients. Conclusion Anti-tumor necrosis factor may be effective for the treatment of moderate to severe psoriasis recalcitrant to traditional therapy.
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2013年第3期187-188,共2页
Chinese Journal of Dermatology
基金
浙江省公益性技术应用研究计划（2011C37003）
温州市科技局基金（Y20080109）
